|

Experimental dose: modified XELOX + sintilimab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Sun Yat-sen University1

Indications

  • Gastric Cancer1
  • Cancer1

Other1 trial

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.